Penumbra
Penumbra is a United States medical-device company focused on minimally invasive treatments for neurovascular and other vascular conditions.
Last updated October 28, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Penumbra, Inc. is an American medical-device company headquartered in Alameda, California. Founded in 2004 by Arani Bose and Adam Elsesser, the company developed its business around interventional technologies intended to treat serious vascular conditions through minimally invasive procedures. Its principal area of specialization is neurovascular care, particularly technologies used in the treatment of ischemic stroke and intracranial aneurysms. The company’s products are used by physicians working through catheter-based approaches rather than open surgery. This positioning places Penumbra at the intersection of medical devices, interventional neuroradiology, vascular surgery, and emergency stroke care. Its portfolio has included aspiration and thrombectomy systems for removing blood clots, embolization and coil technologies for treating aneurysms, and catheter systems designed to access difficult anatomy. The company’s technology strategy has generally emphasized improving access, navigation, clot removal, and procedural control in highly time-sensitive clinical settings. A notable product milestone came in 2014 with the launch of the Apollo system. The system was designed to support minimally invasive removal of deeply located tissue and fluids in the brain, including material associated with otherwise difficult-to-treat blood clots. Penumbra subsequently expanded its presence in neurovascular intervention and developed additional products for stroke and aneurysm procedures. The company has also marketed technologies beyond the narrowest definition of neurovascular intervention, although neurovascular and vascular applications remain central to its identity. Penumbra became a publicly traded company through an initial public offering on the New York Stock Exchange in 2015. It later pursued corporate expansion through acquisitions and strategic investments, including the 2017 acquisition of Italian distributor Crossmed and the 2018 purchase of 40% of the outstanding shares of virtual-reality joint venture MVI Health, according to the referenced company history. These moves reflected an effort to broaden distribution and explore adjacent healthcare-technology applications. The company’s history has also included regulatory, litigation, product-safety, and investor scrutiny. Products associated with Penumbra, including the Penumbra Coil 400 and certain catheter systems, have been subject to recalls or legal claims. A 2016 lawsuit alleged that the Coil 400 caused brain damage after surgery, while later reporting and criticism raised questions about the safety of a specialized catheter used in stroke procedures. These claims and events should be distinguished from final findings of liability or causation; the available reference material does not establish that every allegation was proven. Penumbra also became a target of short sellers in 2020, and requests were reportedly made for investigations by securities and medical-device regulators. In January 2026, Boston Scientific announced a proposed acquisition of Penumbra in a transaction described in the supplied reference material as valued at approximately $15 billion in cash and stock. The transaction was expected to close by the end of 2026, but the available material does not establish that closing had occurred. If completed, the deal would represent a major change in Penumbra’s ownership and corporate position while preserving the strategic importance of its neurovascular-device portfolio.
History
Penumbra was established in 2004 in the United States by Arani Bose and Adam Elsesser. From its beginning, the company concentrated on interventional medical devices, with a particularly strong focus on neurovascular procedures. Its technologies were intended to help physicians reach and treat conditions such as ischemic stroke and intracranial aneurysms through catheter-based procedures. The company’s development reflected the growing importance of endovascular treatment in acute stroke care. Rather than relying on open surgery, neurovascular intervention uses small catheters and related instruments to navigate blood vessels and remove obstructions or deliver treatment. Penumbra built its identity around this minimally invasive model, developing products for clot aspiration, thrombectomy, embolization, and access to challenging areas of the brain and vascular system. In 2011, the company recalled its Penumbra Coil 400. The product later became the subject of a 2016 lawsuit alleging post-surgical brain damage. The available reference material identifies the claim but does not provide a final court ruling or a definitive finding concerning causation. Penumbra launched the Apollo system in 2014. The system was described as enabling minimally invasive removal of deeply seated tissue and fluids in the brain, including otherwise difficult-to-remove blood clots. This launch represented an important expansion of the company’s product platform and reinforced its emphasis on catheter-based neurovascular intervention. In 2015, Penumbra completed an initial public offering on the New York Stock Exchange. Becoming publicly traded provided the company with access to capital markets while increasing disclosure obligations and public scrutiny. The company continued to expand through corporate transactions. In 2017, it acquired Italian distributor Crossmed, supporting its commercial presence in Italy. In 2018, it acquired 40% of the outstanding shares of virtual-reality joint venture MVI Health, an investment that extended beyond the company’s core interventional-device activities. Product-safety issues remained part of Penumbra’s public history. In 2017, the company recalled a 3D revascularization device. In 2020, it recalled a catheter used during heart surgery because of an increased risk of mortality and serious injury, according to the supplied reference material. The same period brought criticism concerning a specialized catheter used in stroke procedures and reports linking the device to patient deaths. Penumbra became a focus of short sellers, and requests were reportedly directed to the Securities and Exchange Commission and the Food and Drug Administration for investigations. The reference material does not establish that those requests resulted in a final enforcement action or regulatory determination. The company’s public narrative also included questions about research supporting the reliability of its products, including an allegation that a scientist cited in connection with favorable research was an internet fabrication. This allegation is presented in the supplied material without enough detail to verify its factual or legal outcome and should not be treated as an established finding. In January 2026, Boston Scientific announced an agreement to acquire Penumbra in a cash-and-stock transaction reportedly worth approximately $15 billion. The supplied source said that the deal was expected to close by the end of 2026. Because the material does not confirm completion, Penumbra’s post-transaction ownership should be treated as unresolved in this dossier.
- 2026
Boston Scientific acquisition announced
[1]Boston Scientific announced a proposed approximately $15 billion cash-and-stock acquisition of Penumbra, with completion expected by the end of the year according to the supplied reference.
- 2020
Catheter recall and investor criticism
[1]Penumbra recalled a catheter used during heart surgery because of reported risks of mortality and serious injury and faced short-seller scrutiny concerning product safety.
- 2018
Investment in MVI Health
[1]The company acquired 40% of the outstanding shares of virtual-reality joint venture MVI Health.
- 2017
Crossmed acquisition and device recall
[1]Penumbra acquired Italian distributor Crossmed and also recalled a 3D revascularization device.
- 2015
Initial public offering
[1]Penumbra completed an initial public offering on the New York Stock Exchange.
- 2014
Apollo system launched
[1]Penumbra introduced the Apollo system for minimally invasive removal of deeply seated tissue and fluids in the brain.
- 2011
Penumbra Coil 400 recall
[1]The company recalled the Penumbra Coil 400.
- 2004
Company founded
[1]Arani Bose and Adam Elsesser founded Penumbra as a medical-device company focused on interventional and neurovascular therapies.
Products and positioning
A specialist medical-device brand focused on catheter-based, minimally invasive treatment of neurovascular and vascular disease, with particular emphasis on emergency stroke intervention and aneurysm care.
Neurovascular thrombectomy and aspiration system
Penumbra System
A catheter-based platform associated with Penumbra’s neurovascular business. It is intended for interventional treatment of vascular blockages, particularly in acute ischemic-stroke procedures, where physicians seek to remove or aspirate clot through a minimally invasive route.
Neurovascular aspiration and tissue-removal system · 2014
Apollo system
Launched in 2014, Apollo was designed to support minimally invasive removal of deeply seated tissue and fluids in the brain. Its purpose was to make selected difficult-to-access intracranial material, including blood clots, more amenable to catheter-based treatment.
Intracranial aneurysm embolization coil
Penumbra Coil 400
An endovascular coil associated with treatment of intracranial aneurysms. The device was recalled in 2011 and later became the subject of litigation alleging patient injury. The available material does not specify its current commercial status.
Neurovascular revascularization device
3D revascularization device
A Penumbra revascularization product that was recalled in 2017. The supplied references do not provide sufficient technical or commercial information to describe its design or current availability in greater detail.
Cardiovascular catheter
Penumbra catheter used in heart surgery
A catheter used in heart-surgery procedures that was recalled in 2020 because of an increased risk of mortality and serious injury, according to the supplied reference material. The specific product name and current status are not identified.
Controversies
2020
Product-safety and short-seller criticism
Penumbra faced criticism concerning a specialized catheter reportedly linked to deaths of stroke patients and became a target of short sellers. Requests for possible SEC and FDA investigations were reportedly made, but the supplied material does not document a final regulatory outcome.
2020
Penumbra responds to short-seller allegations
Penumbra responded to recent short-seller attacks, calling the information about scientific research published by its co-founder inaccurate and misleading. The company said it was reviewing its options for further response.
2016
Litigation concerning Penumbra Coil 400
A lawsuit alleged that the Penumbra Coil 400 caused brain damage after surgery. The available source does not establish a final finding of liability or confirm the allegation.
Brand decisions
2026
Proposed acquisition by Boston ScientificM&ABackground
Boston Scientific announced a strategic transaction to acquire Penumbra and its neurovascular and vascular-device portfolio.
Action taken
Boston Scientific announced a cash-and-stock acquisition reportedly valued at approximately $15 billion.
Aftermath
The deal was expected to close by the end of 2026 according to the supplied reference. Completion and any post-closing integration remain unconfirmed here.
Announced transaction value. (January 2026 announcement)
2018
Investment in MVI HealthM&ABackground
The company explored an adjacent healthcare-technology opportunity involving virtual reality.
Action taken
Penumbra acquired 40% of the outstanding shares of virtual-reality joint venture MVI Health.
Aftermath
The transaction broadened Penumbra’s corporate interests beyond its core interventional-device portfolio, but the supplied material gives no further outcome.
2017
Acquisition of CrossmedM&ABackground
Penumbra pursued international commercial expansion for its medical-device business.
Action taken
The company acquired Italian distributor Crossmed.
Aftermath
The acquisition supported Penumbra’s distribution presence in Italy; further performance details are not provided.
2015
Public listingStrategyBackground
After developing a specialist interventional-device business, Penumbra entered the public capital markets.
Action taken
The company completed an initial public offering on the New York Stock Exchange.
Aftermath
The listing increased access to public financing and subjected the company to greater market and regulatory disclosure scrutiny.
2014
Launch of the Apollo systemProduct launchBackground
Penumbra sought to expand minimally invasive treatment options for deeply located intracranial tissue, fluids, and blood clots.
Action taken
The company introduced the Apollo system for catheter-based removal of difficult-to-access material in the brain.
Aftermath
The launch strengthened Penumbra’s position in neurovascular intervention, although the supplied material does not provide quantitative commercial results.
Recent events
Reported
Penumbra reports quarterly earnings results[4]
Penumbra issued quarterly earnings data, reporting $1.07 earnings per share, below the $1.20 consensus estimate, and revenue of $410.15 million.
Reported
Penumbra responds to short-seller allegations[3]
Penumbra responded to recent short-seller attacks, calling the information about scientific research published by its co-founder inaccurate and misleading. The company said it was reviewing its options for further response.
Reported
Penumbra and RapidAI partner on pulmonary embolism solutions[5]
Penumbra announced a partnership with RapidAI to develop clinical and communications modules intended to support faster clinical decision-making for pulmonary embolism diagnosis and procedures.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/penumbra · Editorial policy · How profiles are compiled